Hypersensitivity Pneumonitis Market Segmentation:
Treatment Segment Analysis
The corticosteroids segment is estimated to account for 60% share of the global hypersensitivity pneumonitis market in the coming years owing to the benefits provided by this treatment. Corticosteroids are considered in patients with severe lung function impairment as both low-dose oral corticosteroids provide adequate initial treatment of acute hypersensitivity pneumonitis. Corticosteroids improve survival and slow fibrotic progression in a matched cohort and the therapy may accelerate the initial recovery in persons with severe disease. For instance, corticosteroids such as prednisone usually 60 mg orally once a day for 1 to 2 weeks, are prescribed for severe symptoms or significant lung dysfunction.
End-User Segment Analysis
Hypersensitivity pneumonitis market from the hospital segment is set to garner a notable share shortly on account of growing advancements in diagnostic techniques. Hospitals are equipped with advanced tools for diagnosis of various diseases including hypersensitivity pneumonitis. This may lead to more patients visiting hospitals for managing acute to severe cases of hypersensitivity pneumonitis.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Treatment |
|
|
End-User |
|
